Abstract
BackgroundDespite the approval of the new janus kinase inhibitors (JAKi) for rheumatoid arthritis (RA) treatment, the real world data on the drug effectiveness of biologic DMARDs (bDMARDs) and targeted synthetic...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
